{
  "nctId": "NCT02932943",
  "briefTitle": "A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)",
  "officialTitle": "A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder",
  "protocolDocument": {
    "nctId": "NCT02932943",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2018-12-07",
    "uploadDate": "2019-09-21T11:57",
    "size": 959963,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02932943/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 465,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-10-15",
    "completionDate": "2018-11-08",
    "primaryCompletionDate": "2018-09-21",
    "firstSubmitDate": "2016-10-12",
    "firstPostDate": "2016-10-13"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD\n* Current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Visit 1\n* Have no more than partial response (\\< 50% improvement) to ongoing treatment with a protocol-allowed antidepressant\n* If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test.\n\nExclusion Criteria:\n\n* DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1\n* Lifetime history of meeting DSM-5 criteria for:\n\n  1. Schizophrenia spectrum or other psychotic disorder\n  2. Bipolar or related disorder\n  3. Major neurocognitive disorder\n  4. Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study\n  5. Dissociative disorder\n  6. Posttraumatic stess disorder\n  7. MDD with psychotic features\n* Significant suicide risk, as judged by the Investigator.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Trial",
        "description": "The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.",
        "timeFrame": "Baseline and 3 Weeks"
      }
    ],
    "secondary": [
      {
        "measure": "Change From Baseline in MADRS Total Score",
        "description": "The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.",
        "timeFrame": "Baseline and Day 8"
      },
      {
        "measure": "Change From Baseline to Day 21 in MADRS Total Score for the Placebo Non-responders of mITT Population",
        "description": "The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.",
        "timeFrame": "Baseline and Day 21"
      },
      {
        "measure": "Change From Baseline to Day 8 in MADRS Total Score for the Placebo Non-responders of mITT Population",
        "description": "The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.",
        "timeFrame": "Baseline and Day 8"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 54,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:19.003Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}